Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Individualized Anti-Cancer Vaccine (CRCL-ALLOVAX) in Advanced Hepatocellular Carcinoma
TCTR20150802001Phase 2Not yet recruiting
- Sponsor
- Immunovative Therapies
- Start
- Jun 2016
- Countries
- 1
01
Overview
Phase 2, single-arm trial in hepatocellular carcinoma (HCC), sponsored by Immunovative Therapies. Planned start Jun 2016; status: not yet recruiting.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on TCTR20150802001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20150802001.